Skip to content

Indonesia After Discharge LBW Infant HMF Supplementation Study

Growth and Body Composition of Low Birth Weight Infants Supplemented With Human Milk Fortifier After Discharge: A Double-Blind Randomized Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04954807
Acronym
DAHLIA
Enrollment
163
Registered
2021-07-08
Start date
2020-12-08
Completion date
2022-02-25
Last updated
2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Feeding, Exclusive, Gestational Age and Weight Conditions, Low; Birthweight

Keywords

Low Birth Weight, Breast Feeding, Body Mass Index, Human Milk Fortifier, Small Gestational Age

Brief summary

Low birth weight (LBW) infant (1800-2449 gram) will be given the new human milk fortifier (HMF) which contains protein, lipid, carbohydrate and micronutrients after discharge. Human Milk Fortifier or placebo (carbohydrate only with similar calorie content) will be provided until 3 months of age. The investigators want to evaluate if the addition of HMF to mother's milk while breastfeeding LBW infants after discharge influences growth and body composition up to 3 months of age.

Detailed description

This is a prospective two arms parallel double-blind randomized clinical trial in LBW infants. Clinically healthy LBW infants discharge on oral feeding of human milk before 2 weeks of age (\< 15 days old) will be invited to participate in the study. Exclusively or predominantly breastfed infants will be encourage to use finger feeding as method of supplementation, but mothers can choose their own preferences if they wish to do so. After signing the informed consent by parent, subject will be randomized to one of four group. Randomization list were prepare by one investigator who do not involve in recruitment, outcome measures and statistical analysis. Study product will be labeled as A, B, C D in similar tin. Only manufacturer know the content of these tins and the code will be revealed after statistical analysis completed. Parents will be given this 200 g tin of study product and ask to return the tin after 14 days of opening. Unblinded assistant will weight the tin before and after opening to estimate the HMF intake for 14 days. This study will be conducted in several hospitals in Greater Jakarta. Adherence to study protocol will be encouraged during face to face session initially in dispensing study product and subsequent visits (visit 1 at one-month-old, visit 2 at two months old). These sessions will include the reminder of the importance of following study protocol, breastfeeding support if needed and discussion about difficulties that arise. The investigators will also remind mothers via text to fill in three days diary of intake one week before each visit.

Interventions

DIETARY_SUPPLEMENThuman milk fortified

HMF will be given 6 scoops a day

DIETARY_SUPPLEMENTplacebo

Placebo will be given six scoops a day

Sponsors

Ludwig-Maximilians - University of Munich
CollaboratorOTHER
Indonesia University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

One investigator who do not involve in recruitment and outcome measures will generate randomization list by computer application and set up the list into Redcap randomization set up. No one except him will know the sequence of randomization. Research assistant will randomize subjects into one of four group according to Redcap assignment. The manufacturer prepare the study product into four groups: A,B,C,D and kept the code until the statistical analysis completed. All investigators, care providers and study subjects aware of the active or placebo group. Research assistants who recruit the study subject are not allowed to open the tin. One research assistant who does no meet study subject will measure the weight of tin before and after the supplementation. Subject only meet with researchers individually and will not meet other subjects so they will not know the content of the other tin.

Intervention model description

Subjects in the intervention group will be given the new human milk fortifier which contains protein, lipid, carbohydrate and micronutrients while the control group will receive placebo (polysaccharides 0.9 g/1 g placebo and maltose 0.1 g/1 g placebo and minerals). Assuming the average weight is 2 Kg, 6 scoops (@1.0 g) will provide 1.95 g protein and 25.5 Kcal in the intervention group while 6 scoops of 1.1 g in the control group will provide 26.4 Kcal with no protein. Three times a day, supplementation with 2.0 gram (intervention group) or 2.2 gram (control group) of study product will be provided, regardless of the actual weight of the subject. Both groups will receive iron supplementation 2 drops daily (5 mg elemental iron in forms of Fe III hydroxide polymaltose complex) since 2 month old as a routine supplementation recommended by Indonesian Pediatrics Society.

Eligibility

Sex/Gender
ALL
Age
1 Days to 14 Days
Healthy volunteers
Yes

Inclusion criteria

1. Low birth weight infants (1800-2499 g) with oral feeding 2. Exclusively breastfed or predominantly breastfed (consuming term infant formula less than 50 ml/Kg BW/day) at discharge 3. Discharge from the hospital before 2 weeks of age and maximal age of enrolment is 14 days old 4. Live in greater Jakarta 5. Parents agree in writing to study participation and indicate their intention to follow study procedures.

Exclusion criteria

Any subject who has major congenital anomaly or any other disorder(s) that infers with normal feeding, growth, and neurodevelopment. Participating in another intervention trial

Design outcomes

Primary

MeasureTime frameDescription
Gaining weightthree months of ageGain in weight (g/kg initial weight & difference) between study enrolment and three months of age

Secondary

MeasureTime frameDescription
Average weight gainenrollment to three months of ageAverage daily weight gain (g/kg/day) from enrolment to at three months of age
Gaining lengthThree months of ageGain in length (mm initial length & difference) from study enrolment to the age of 3 months
Head circumferenceThree months of ageGain in head circumference (mm initial head circumference & difference) from study enrolment to the age of 3 months
Weight for ageThree months of ageDifference of weight for age (Z score) from study enrolment to the age of 3 months
Body fat percentageThree months of ageDifference in body fat percentage between groups
Feverenrollment to three months of ageNumber of subjects who reported to experience fever between groups
Stool frequencyenrollment to three months of ageaverage stool frequency per day between groups
Vomitenrollment to three months of ageNumber of subjects who reported to have vomit between groups
Bloatingenrollment to three months of ageNumber of subjects who reported to experience bloating between groups
Rehospitalizationenrollment to three months of ageNumber of subjects who reported being hospitalized between groups
Stool consistencyenrollment to three months of ageMedian type of stools according to Diapered Infant stool chart between groups

Countries

Indonesia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026